ATE420182T1 - Verpackungszellinien in der verwendung zur erleichterung der entwicklung hocheffizienter adenoviraler vektoren - Google Patents

Verpackungszellinien in der verwendung zur erleichterung der entwicklung hocheffizienter adenoviraler vektoren

Info

Publication number: ATE420182T1
Authority: AT; Austria
Prior art keywords: polypeptide; encoding; dna sequence; plasmid; fibre
Prior art date: 1996-09-25

Application number

AT04014954T

Other languages

English (en)

Inventor

Glen R Nemerow

Seggern Daniel J Von

Original Assignee

Scripps Research Inst

Novartis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-25

Filing date

1997-09-24

Publication date

2009-01-15

1997-09-24 Application filed by Scripps Research Inst, Novartis Pharma Gmbh filed Critical Scripps Research Inst

2009-01-15 Application granted granted Critical

2009-01-15 Publication of ATE420182T1 publication Critical patent/ATE420182T1/de

Links

238000004806 packaging method and process Methods 0.000 title abstract 4
239000013598 vector Substances 0.000 title 1
229920001184 polypeptide Polymers 0.000 abstract 9
102000004196 processed proteins & peptides Human genes 0.000 abstract 9
108090000765 processed proteins & peptides Proteins 0.000 abstract 9
239000013612 plasmid Substances 0.000 abstract 7
108091028043 Nucleic acid sequence Proteins 0.000 abstract 5
239000012634 fragment Substances 0.000 abstract 5
239000013603 viral vector Substances 0.000 abstract 5
239000000835 fiber Substances 0.000 abstract 4
230000001225 therapeutic effect Effects 0.000 abstract 3
230000035772 mutation Effects 0.000 abstract 2
239000002245 particle Substances 0.000 abstract 2
230000003612 virological effect Effects 0.000 abstract 2
CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 abstract 1
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 abstract 1
101710172711 Structural protein Proteins 0.000 abstract 1
230000037430 deletion Effects 0.000 abstract 1
238000012217 deletion Methods 0.000 abstract 1
102000034356 gene-regulatory proteins Human genes 0.000 abstract 1
108091006104 gene-regulatory proteins Proteins 0.000 abstract 1
239000002773 nucleotide Substances 0.000 abstract 1
125000003729 nucleotide group Chemical group 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
241000701161 unidentified adenovirus Species 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10345—Special targeting system for viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
- C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
- C12N2810/6018—Adenoviridae

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Medicinal Chemistry (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Manufacturing & Machinery (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
General Chemical & Material Sciences (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Hybrid Cells (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Packages (AREA)

AT04014954T 1996-09-25 1997-09-24 Verpackungszellinien in der verwendung zur erleichterung der entwicklung hocheffizienter adenoviraler vektoren ATE420182T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US71980696A	1996-09-25	1996-09-25

Publications (1)

Publication Number	Publication Date
ATE420182T1 true ATE420182T1 (de)	2009-01-15

Family

ID=24891439

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04014954T ATE420182T1 (de)	1996-09-25	1997-09-24	Verpackungszellinien in der verwendung zur erleichterung der entwicklung hocheffizienter adenoviraler vektoren

Country Status (9)

Country	Link
EP (2)	EP1471146B1 (de)
JP (2)	JP4350800B2 (de)
AT (1)	ATE420182T1 (de)
AU (1)	AU4624197A (de)
CA (1)	CA2266342C (de)
DE (1)	DE69739211D1 (de)
IL (1)	IL128958A0 (de)
NZ (2)	NZ334827A (de)
WO (1)	WO1998013499A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5846782A (en)	1995-11-28	1998-12-08	Genvec, Inc.	Targeting adenovirus with use of constrained peptide motifs
US6465253B1 (en)	1994-09-08	2002-10-15	Genvec, Inc.	Vectors and methods for gene transfer to cells
US5770442A (en)	1995-02-21	1998-06-23	Cornell Research Foundation, Inc.	Chimeric adenoviral fiber protein and methods of using same
US6127525A (en) *	1995-02-21	2000-10-03	Cornell Research Foundation, Inc.	Chimeric adenoviral coat protein and methods of using same
US6783980B2 (en)	1995-06-15	2004-08-31	Crucell Holland B.V.	Packaging systems for human recombinant adenovirus to be used in gene therapy
US7232899B2 (en)	1996-09-25	2007-06-19	The Scripps Research Institute	Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
JP2002512805A (ja)	1998-04-29	2002-05-08	オクラホマメディカルリサーチファウンデーション	アデノウイルスベクターおよびレトロウイルスベクターからのレトロウイルスプロデューサー細胞の構築
AU4070499A (en)	1998-04-30	1999-11-16	Cornell Research Foundation Inc.	Adenoviral vectors with tandem fiber proteins
IL141403A0 (en)	1998-08-28	2002-03-10	Univ Duke	Deleted adenoviruses and methods of making and administering the same
US6900049B2 (en)	1998-09-10	2005-05-31	Cell Genesys, Inc.	Adenovirus vectors containing cell status-specific response elements and methods of use thereof
AU767975B2 (en) *	1998-09-11	2003-11-27	Genvec, Inc.	Alternatively targeted adenovirus
IT1302403B1 (it)	1998-11-06	2000-09-05	Angeletti P Ist Richerche Bio	Cellule per la produzione di vettori adenovirali difettivi, metodoper la loro preparazione e loro uso.
US6929946B1 (en)	1998-11-20	2005-08-16	Crucell Holland B.V.	Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
AU772630B2 (en) *	1999-01-14	2004-05-06	Novartis Ag	Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
US6913922B1 (en)	1999-05-18	2005-07-05	Crucell Holland B.V.	Serotype of adenovirus and uses thereof
WO2003104467A1 (en)	2002-04-25	2003-12-18	Crucell Holland B.V.	Means and methods for the production of adenovirus vectors
US6492169B1 (en)	1999-05-18	2002-12-10	Crucell Holland, B.V.	Complementing cell lines
US6740511B1 (en)	1999-08-27	2004-05-25	Transgene S.A.	Modified adenoviral fibre and uses thereof
WO2001044280A2 (en) *	1999-12-14	2001-06-21	Genovo, Inc.	Methods and compositions for the manufacture of replication incompetent adenovirus
JP2003534805A (ja) *	2000-05-31	2003-11-25	ユニバーシティオブサスカチュワン	変化した親和性を有する改変ウシアデノウイルス
DE60138403D1 (de)	2000-09-26	2009-05-28	Crucell Holland Bv	Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
US6946126B2 (en) *	2001-06-04	2005-09-20	Duke University	Replicating adenovirus vectors
US7482156B2 (en)	2003-10-15	2009-01-27	Cell Genesys, Inc.	Hepatocellular carcinoma specific promoter and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2144040A1 (fr) *	1993-07-13	1995-01-26	Michel Perricaudet	Vecteurs adenoviraux defectifs et utilisation en therapie genique
DE69435223D1 (de) *	1993-10-25	2009-09-03	Canji Inc	Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
US6312699B1 (en) *	1994-03-28	2001-11-06	Uab Research Foundation	Ligands added to adenovirus fiber
US7252989B1 (en) *	1994-04-04	2007-08-07	Board Of Regents, The University Of Texas System	Adenovirus supervector system
US5851806A (en) *	1994-06-10	1998-12-22	Genvec, Inc.	Complementary adenoviral systems and cell lines
EP0784690B1 (de) *	1994-06-10	2006-08-16	Genvec, Inc.	Adenoviren-vektor systeme und zelllinien
US5559099A (en) *	1994-09-08	1996-09-24	Genvec, Inc.	Penton base protein and methods of using same
US5872005A (en) *	1994-11-03	1999-02-16	Cell Genesys Inc.	Packaging cell lines for adeno-associated viral vectors
IL116816A (en) *	1995-01-20	2003-05-29	Rhone Poulenc Rorer Sa	Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5770442A (en) *	1995-02-21	1998-06-23	Cornell Research Foundation, Inc.	Chimeric adenoviral fiber protein and methods of using same

1997
- 1997-09-24 EP EP04014954A patent/EP1471146B1/de not_active Expired - Lifetime
- 1997-09-24 NZ NZ334827A patent/NZ334827A/xx unknown
- 1997-09-24 IL IL12895897A patent/IL128958A0/xx unknown
- 1997-09-24 EP EP97944892A patent/EP0937150A2/de not_active Withdrawn
- 1997-09-24 AU AU46241/97A patent/AU4624197A/en not_active Abandoned
- 1997-09-24 AT AT04014954T patent/ATE420182T1/de not_active IP Right Cessation
- 1997-09-24 DE DE69739211T patent/DE69739211D1/de not_active Expired - Lifetime
- 1997-09-24 CA CA2266342A patent/CA2266342C/en not_active Expired - Fee Related
- 1997-09-24 NZ NZ508399A patent/NZ508399A/xx unknown
- 1997-09-24 WO PCT/EP1997/005251 patent/WO1998013499A2/en not_active Ceased
- 1997-09-24 JP JP51527398A patent/JP4350800B2/ja not_active Expired - Fee Related
2008
- 2008-12-04 JP JP2008309748A patent/JP2009072205A/ja active Pending

Also Published As

Publication number	Publication date
NZ508399A (en)	2003-06-30
WO1998013499A2 (en)	1998-04-02
JP4350800B2 (ja)	2009-10-21
JP2001505047A (ja)	2001-04-17
CA2266342C (en)	2010-06-08
DE69739211D1 (de)	2009-02-26
IL128958A0 (en)	2000-02-17
AU4624197A (en)	1998-04-17
WO1998013499A3 (en)	1998-08-27
NZ334827A (en)	2001-02-23
EP1471146B1 (de)	2009-01-07
EP0937150A2 (de)	1999-08-25
EP1471146A3 (de)	2005-03-30
CA2266342A1 (en)	1998-04-02
EP1471146A2 (de)	2004-10-27
JP2009072205A (ja)	2009-04-09

Legal Events

Date	Code	Title	Description
2009-07-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69739211D1 (de)	2009-02-26	Verpackungszellinien in der Verwendung zur Erleichterung der Entwicklung hocheffizienter adenoviraler Vektoren
Louis et al.	1994	Cell-binding domain of adenovirus serotype 2 fiber
Krasnykh et al.	1998	Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob
Fallaux et al.	1996	Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors
Stevenson et al.	1995	Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain
Anderson et al.	1989	Characterization of the adenovirus 2 virion protein, mu
Legrand et al.	1999	Fiberless recombinant adenoviruses: virus maturation and infectivity in the absence of fiber
Jakubczak et al.	2001	Adenovirus type 5 viral particles pseudotyped with mutagenized fiber proteins show diminished infectivity of coxsackie B-adenovirus receptor-bearing cells
Yeh et al.	1997	Advances in adenoviral vectors: from genetic engineering to their biology
Koizumi et al.	2003	Generation of fiber‐modified adenovirus vectors containing heterologous peptides in both the HI loop and C terminus of the fiber knob
Wickham et al.	1995	Targeting Of adenovirus penton base to new receptors through replacement of its FGD motif with other
Rosa-Calatrava et al.	2001	Functional analysis of adenovirus protein IX identifies domains involved in capsid stability, transcriptional activity, and nuclear reorganization
US6312699B1 (en)	2001-11-06	Ligands added to adenovirus fiber
DE69430071D1 (de)	2002-04-11	Herstellung von rekombinanten proteinen in einem rinderadenovirus-expressionsvektorsystem
Philipson	1983	Structure and assembly of adenoviruses
HUP0200073A2 (hu)	2002-05-29	Célzott adenovírus vektorok heterológ gének beadására
MXPA00012617A (es)	2002-08-20	Adenovirus recombinante con replicacion defectuosa con un promotor tardio principal mutado.
IS4754A (is)	1998-05-25	Genaferjur og aðferðir fyrir genaflutning inn í frumur
WO1999011764A3 (en)	1999-06-10	Methods for generating high titer helper-free preparations of recombinant aav vectors
EP0979101A4 (de)	2003-03-12	Rekombinanter hunde-adenovirus (cav), welcher exogene dna enthält
Glenn et al.	1985	Adenovirus 5 early region 1A host range mutants hr3, hr4, and hr5 contain point mutations which generate single amino acid substitutions
Lusky et al.	1999	Regulation of adenovirus-mediated transgene expression by the viral E4 gene products: requirement for E4 ORF3
CA2229631A1 (en)	1997-02-27	Gene therapy using ovine adenoviral vectors
Sussenbach	1984	The structure of the genome
CA2378586A1 (en)	2001-01-18	Replication-competent anti-cancer vectors